Literature DB >> 8936347

Adenosine receptor ligands: differences with acute versus chronic treatment.

K A Jacobson1, D K von Lubitz, J W Daly, B B Fredholm.   

Abstract

Adenosine receptors have been the target of intense research with respect to potential use of selective ligands in a variety of therapeutic areas. Caffeine and theophylline are adenosine receptor antagonists, and over the past three decades a wide range of selective agonists and antagonists for adenosine receptor subtypes have been developed. A complication to the therapeutic use of adenosine receptor ligands is the observation that the effects of acute administration of a particular ligand can be diametrically opposite to the chronic effects of the same ligand. This 'effect inversion' is discussed here by Ken Jacobson and colleagues, and has been observed for effects on cognitive processes, seizures and ischaemic damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8936347      PMCID: PMC3431161          DOI: 10.1016/0165-6147(96)10002-x

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  45 in total

Review 1.  Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

Authors:  J Linden
Journal:  Trends Pharmacol Sci       Date:  1994-08       Impact factor: 14.819

2.  Cross-tolerance studies between caffeine and (-)-N6-(phenylisopropyl)-adenosine (PIA) in mice.

Authors:  M K Ahlijanian; A E Takemori
Journal:  Life Sci       Date:  1986-02-17       Impact factor: 5.037

3.  N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors.

Authors:  H J Normile; R A Barraco
Journal:  Brain Res Bull       Date:  1991-07       Impact factor: 4.077

4.  Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.

Authors:  D K Von Lubitz; R C Lin; N Melman; X D Ji; M F Carter; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1994-04-21       Impact factor: 4.432

5.  Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.

Authors:  B E Garrett; S G Holtzman
Journal:  Eur J Pharmacol       Date:  1994-09-01       Impact factor: 4.432

6.  A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.

Authors:  J P Hannon; H J Pfannkuche; J R Fozard
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

Review 7.  Neuroprotective role of adenosine in cerebral ischaemia.

Authors:  K A Rudolphi; P Schubert; F E Parkinson; B B Fredholm
Journal:  Trends Pharmacol Sci       Date:  1992-12       Impact factor: 14.819

8.  The effects of adenosine A3 receptor stimulation on seizures in mice.

Authors:  D K Von Lubitz; M F Carter; S I Deutsch; R C Lin; J Mastropaolo; Y Meshulam; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1995-02-24       Impact factor: 4.432

9.  The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate.

Authors:  E Bona; U Adén; B B Fredholm; H Hagberg
Journal:  Pediatr Res       Date:  1995-09       Impact factor: 3.756

Review 10.  Adenosine: a prototherapeutic concept in neurodegeneration.

Authors:  D K von Lubitz; M F Carter; M Beenhakker; R C Lin; K A Jacobson
Journal:  Ann N Y Acad Sci       Date:  1995-09-15       Impact factor: 5.691

View more
  57 in total

1.  A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice.

Authors:  J F Chen; Z Huang; J Ma; J Zhu; R Moratalla; D Standaert; M A Moskowitz; J S Fink; M A Schwarzschild
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

2.  Activation of Trk neurotrophin receptors in the absence of neurotrophins.

Authors:  F S Lee; M V Chao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 4.  Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.

Authors:  Sergi Ferré
Journal:  Psychopharmacology (Berl)       Date:  2016-01-20       Impact factor: 4.530

Review 5.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

6.  Purine receptors: GPCR structure and agonist design.

Authors:  Kenneth A Jacobson; Soo-Kyung Kim; Stefano Costanzi; Zhan-Guo Gao
Journal:  Mol Interv       Date:  2004-12

7.  Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers.

Authors:  Francisco Ciruela; Vicent Casadó; Ricardo J Rodrigues; Rafael Luján; Javier Burgueño; Meritxell Canals; Janusz Borycz; Nelson Rebola; Steven R Goldberg; Josefa Mallol; Antonio Cortés; Enric I Canela; Juan F López-Giménez; Graeme Milligan; Carme Lluis; Rodrigo A Cunha; Sergi Ferré; Rafael Franco
Journal:  J Neurosci       Date:  2006-02-15       Impact factor: 6.167

8.  Chronic effects of xanthines on levels of central receptors in mice.

Authors:  D Shi; J W Daly
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

9.  Acute caffeine treatment increases extracellular nucleotide hydrolysis from rat striatal and hippocampal synaptosomes.

Authors:  Rosane Souza da Silva; Alessandra Nejar Bruno; Ana Maria Oliveira Battastini; João José Freitas Sarkis; Diogo Rizzato Lara; Carla Denise Bonan
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.